Deerfield Management’s Epizyme, Inc EPZM Stock Holding History

Deerfield Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,779,094	Closed	-$18.9M	–	110
2018 Q3	$18.9M	Buy	1,779,094 +140,094	+9%	+$1.6M	0.68%	50
2018 Q2	$22.2M	Buy	1,639,000 +678,030	+71%	+$10.6M	0.78%	49
2018 Q1	$17.1M	Sell	960,970 -48,556	-5%	-$820K	0.59%	61
2017 Q4	$12.7M	Buy	1,009,526 +309,000	+44%	+$4.49M	0.5%	59
2017 Q3	$13.3M	Buy	700,526 +38,157	+6%	+$582K	0.6%	55
2017 Q2	$10M	Sell	662,369 -751,227	-53%	-$11.4M	0.53%	55
2017 Q1	$24.2M	Sell	1,413,596 -187,453	-12%	-$2.5M	0.94%	39
2016 Q4	$19.4M	Buy	1,601,049 +1,309,870	+450%	+$13.7M	0.8%	40
2016 Q3	$2.87M	Sell	291,179 -331,120	-53%	-$3.02M	0.13%	74
2016 Q2	$6.37M	Buy	+622,299	New	+$6.94M	0.25%	65

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deerfield Management's EPZM Position: Q4 2018 in Review

Deerfield Management sold out of Epizyme, Inc (EPZM) in Q4 2018, closing a stake of 1,779,094 shares — an estimated $18.9M sold.

Deerfield Management first reported a position in EPZM in Q2 2016 and held it in 10 quarters. The position peaked at $24.2M in Q1 2017. 105 funds tracked by Wall St. Rank hold EPZM as of Q4 2018.

Deerfield Management reported no remaining Epizyme, Inc position as of Q4 2018 after selling out during the quarter.
Deerfield Management sold 1,779,094 Epizyme, Inc shares in Q4 2018, an estimated $18.9M.
Deerfield Management first reported a position in Epizyme, Inc in Q2 2016 and held it in 10 quarters.
Deerfield Management's Epizyme, Inc position peaked at $24.2M in Q1 2017.
105 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2018.

Based on Deerfield Management's 13F filing for Q4 2018, filed 14 Feb 2019.